B2M HLA-A*24:02 Lentivirus

B2M HLA-A*24:02 Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses result in the expression of B2M (beta-2 microglobulin) HLA (human leukocyte antigen)-A*24:02 driven by an EF1a promoter. The lentiviruses also contain a puromycin selection marker (Figure 1). Figure 1. Schematic of the lenti-vector used to generate B2M HLA-A*24:02 Lentivirus. Human Leukocyte Antigen-A (HLA-A) is an MHC-I (major histocompatibility complex) heavy chain receptor, composed of HLA-A and beta2-microglobulin (B2M). There are over 200 genes encoding HLA variants and this variability plays a critical role in adaptive immunity. HLA-A*24:02 was found to be a common risk factor in anti-epileptic drug cutaneous adverse effects, which resulted in a recommendation to perform HLA pre-screening prior to drug administration. Since its prevalence in Asia is higher than HLA-A*02:01, the use of an HLA-A*24:02-restricted peptide targeting AFP (alpha-fetoprotein) may prove beneficial for HCC (hepatocellular) treatment. The understanding of the association between HLA alleles and diseases will allow a refinement of therapeutic strategies.